Oncological and Functional Outcomes After Organ-Sparing Plastic Reconstructive Surgery for Penile Cancer.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
08 2020
Historique:
received: 12 02 2020
revised: 21 03 2020
accepted: 22 03 2020
pubmed: 8 5 2020
medline: 3 2 2022
entrez: 8 5 2020
Statut: ppublish

Résumé

To describe oncological and functional outcomes in patients treated with reconstructive organ-sparing surgery (OSS) for squamous cell carcinoma of the penis. Plastic reconstructive OSS of the penis with a split thickness skin graft has been proposed as a treatment option for penile cancer, with the objective being preservation of physiological voiding and sexual function without comprising oncological control. Multicenter study reporting clinicopathological data of 57 patients with malignant lesions of the penis treated with OSS and plastic reconstructive surgery with split thickness skin graft from 2007 to 2019. Health related quality of life (HRQoL) was assessed with EuroQoL-5D-3L, urinary symptoms with the International Consultation on Incontinence Modular Questionnaire for Male Lower Urinary Tract Symptoms, and erectile function with the International Index of erectile function (IIEF)-5. Fifty-seven patients underwent OSS reconstructive surgery. Twenty underwent glans resurfacing, 23 partial penectomy, and 14 glansectomy. Median age was 55.1 years (interquartile range [IQR] 29-90), median follow-up 55.7 months (3-149). At the time of data analysis, 6 patients had died of Squamous Cell Carcinoma (SCC) (12.5%) and 10 (17.8%) had progressed. Kaplan-Meier estimates showed a 5-year survival rate of 87.5% and a 5-year progression-free survival of 83%. We assessed HRQoL and functional outcomes in 32 patients. EuroQol 5D-3L showed a mean health status of 82.5%, median Voiding score of the ICIQ-MLTUS was 4 (IQR 1-15), and median IIEF-5 19 (IQR 10.75-25). OSS of the penis remains a safe and viable option for the treatment of SCC, ensuring a favorable appearance of the penis, preserving urinary and sexual function, with good HRQoL and without comprising oncological safety in selected cases.

Identifiants

pubmed: 32380155
pii: S0090-4295(20)30512-4
doi: 10.1016/j.urology.2020.03.058
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-165.e1

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Jaime Pérez (J)

Division of Urology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; Department of Urology, Fundación Santa Fe de Bogotá, Colombia.

Julián Chavarriaga (J)

Division of Urology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia. Electronic address: chavarriagaj@javeriana.edu.co.

Ana Ortiz (A)

Division of Urology, Fundación Oftalmológica de Santander Clínica Ardila Lulle (FOSCAL), Universidad Autonoma de Bucaramanga, Colombia.

Paola Orrego (P)

Division of Urology, Hospital Militar Central, Universidad Militar Nueva Granada, Bogotá, Colombia.

Sandra Rueda (S)

Division of Urology, Fundación Oftalmológica de Santander Clínica Ardila Lulle (FOSCAL), Universidad Autonoma de Bucaramanga, Colombia.

William Quiroga (W)

Division of Urology, Hospital Militar Central, Universidad Militar Nueva Granada, Bogotá, Colombia.

Nicolás Fernandez (N)

Division of Urology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; Department of Urology, Fundación Santa Fe de Bogotá, Colombia; Division of Urology, Hospital for SickKids, University of Toronto, Toronto, Canada.

German Patiño (G)

Division of Urology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

Verónica Tobar (V)

Division of Urology, Fundación Oftalmológica de Santander Clínica Ardila Lulle (FOSCAL), Universidad Autonoma de Bucaramanga, Colombia.

Nicolás Villareal (N)

Division of Urology, Fundación Oftalmológica de Santander Clínica Ardila Lulle (FOSCAL), Universidad Autonoma de Bucaramanga, Colombia.

Juan Prada (J)

Division of Urology, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

Catalina Barco (C)

Department of Urology, Fundación Santa Fe de Bogotá, Colombia.

Guillermo Sarmiento (G)

Division of Urology, Fundación Oftalmológica de Santander Clínica Ardila Lulle (FOSCAL), Universidad Autonoma de Bucaramanga, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH